Abstract
Fifteen patients with recurrent squamous carcinoma of the head and neck received high-dose cytosine arabinoside (ara-C) (3 g/m2) and cisplatin (100 mg/m2) every 3 weeks in an attempt to explore the dose-dependent synergy between these two agents. A partial response was attained in one patient; there were no complete responses. The major toxicity was myelosuppression. With the current schedule, high-dose ara-C failed to improve the response rate achieved with cisplatin alone.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Squamous Cell / drug therapy*
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Drug Administration Schedule
-
Drug Evaluation
-
Female
-
Head and Neck Neoplasms / drug therapy*
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*